{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:14:20Z","timestamp":1777637660157,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/leu.2013.312","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T06:34:43Z","timestamp":1382682883000},"page":"973-975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience"],"prefix":"10.1038","volume":"28","author":[{"given":"P","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Daver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Cardenas-Turanzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Garris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"BFleu2013312_CR1","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood 2009; 114: 5136\u20135145.","journal-title":"Blood"},{"key":"BFleu2013312_CR2","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","volume":"104","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104: 1624\u20131630.","journal-title":"Blood"},{"key":"BFleu2013312_CR3","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","volume":"102","author":"CO Rodriguez Jr.","year":"2003","unstructured":"Rodriguez CO Jr., Stellrecht CM, Gandhi V . Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003; 102: 1842\u20131848.","journal-title":"Blood"},{"key":"BFleu2013312_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4137\/CMO.S4364","volume":"4","author":"AM Roecker","year":"2010","unstructured":"Roecker AM, Stockert A, Kisor DF . Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol 2010; 4: 133\u2013141.","journal-title":"Clin Med Insights Oncol"},{"key":"BFleu2013312_CR5","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","volume":"16","author":"V Gandhi","year":"1998","unstructured":"Gandhi V, Plunkett W, Rodriguez CO Jr., Nowak BJ, Du M, Ayres M et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 1998; 16: 3607\u20133615.","journal-title":"J Clin Oncol"},{"key":"BFleu2013312_CR6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1200\/JCO.2000.18.5.995","volume":"18","author":"DF Kisor","year":"2000","unstructured":"Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000; 18: 995\u20131003.","journal-title":"J Clin Oncol"},{"key":"BFleu2013312_CR7","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23: 3376\u20133382.","journal-title":"J Clin Oncol"},{"key":"BFleu2013312_CR8","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"DJ DeAngelo","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007; 109: 5136\u20135142.","journal-title":"Blood"},{"key":"BFleu2013312_CR9","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","volume":"118","author":"N Gokbuget","year":"2011","unstructured":"Gokbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011; 118: 3504\u20133511.","journal-title":"Blood"},{"key":"BFleu2013312_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.bbmt.2013.04.010","volume":"19","author":"E Forcade","year":"2013","unstructured":"Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transpl 2013; 19: 1124\u20131126.","journal-title":"Biol Blood Marrow Transpl"},{"key":"BFleu2013312_CR11","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","volume":"12","author":"MH Cohen","year":"2006","unstructured":"Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD Jr, Abraham S et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Clin Cancer Res 2006; 12: 5329\u20135335.","journal-title":"Clin Cancer Res"},{"key":"BFleu2013312_CR12","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","volume":"30","author":"KP Dunsmore","year":"2012","unstructured":"Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 2753\u20132759.","journal-title":"J Clin Oncol"},{"key":"BFleu2013312_CR13","first-page":"327","volume":"18","author":"MC Bene","year":"2004","unstructured":"Bene MC, Groupe d'Etude Immunologique des L, European Group for the Immunological Classification of L. Pro-T ALL: immunophenotypical analyses. J Biol Regul Homeost Agents 2004; 18: 327\u2013330.","journal-title":"J Biol Regul Homeost Agents"},{"key":"BFleu2013312_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.beha.2010.08.002","volume":"23","author":"JP Meijerink","year":"2010","unstructured":"Meijerink JP . Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010; 23: 307\u2013318.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu2013312_CR15","unstructured":"Cancer Therapy Evaluation Program. CTCAE criteria, Version 3.0. (Internet). CTCAE 2012."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013312","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:24:01Z","timestamp":1648740241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFleu2013312"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.312","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,25]]},"assertion":[{"value":"25 October 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}